Lenalidomide in multiple myeloma: Current status and future potential. - Wikidata - wikimedia - TriplyDB

Lenalidomide in multiple myeloma: Current status and future potential.

Lenalidomide in multiple myeloma: Current status and future potential.

http://www.wikidata.org/entity/Q38013995

about

Brain arteriovenous malformation modeling, pathogenesis, and novel therapeutic targets.Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma.Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.Second autologous transplant as salvage therapy in multiple myeloma.Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy.Stability of lenalidomide suspension after preparation by a simple suspension method for enteral tube administration.The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma.Thalidomide Reduces Hemorrhage of Brain Arteriovenous Malformations in a Mouse Model.

P2860

Q33843008-AEA8918C-6BD6-4D37-BEA9-ED4CE6FE2D48 Q33886073-40AE6980-B00E-4D47-AA51-3821F3B462FF Q34734159-CDC24586-A2F4-4F1A-AA21-1B1A85CAA984 Q37233276-8E120C49-96C1-4C7C-9BE4-B1A3D5324389 Q37417591-606FFE9F-0AAF-4003-9730-2189D0A12205 Q38151157-F763B797-1ECD-4BEF-BD24-60C08D27E514 Q38155039-419C5A89-5523-49CB-BC4F-5139A061B895 Q42616581-0CBB6F33-5EEB-4653-AEDB-AC45E5AAF02A Q44449693-CDC02167-518E-4780-AB05-DA946F5CFD4A Q44636774-6198D6E2-1AE0-45A8-BD9C-F897639862FC Q49872152-C828853C-D45A-4738-9CBB-C73979D38EB5 Q51730951-882AC8CE-E6E6-4073-9064-BE37D20B1678

P2860

Lenalidomide in multiple myeloma: Current status and future potential.

http://www.wikidata.org/entity/Q38013995

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Lenalidomide in multiple myeloma: Current status and future potential.

@en

type

label

Lenalidomide in multiple myeloma: Current status and future potential.

@en

prefLabel

Lenalidomide in multiple myeloma: Current status and future potential.

@en

P1433

Q38013995-111818E5-91BB-4743-9E7D-5A7E26B20F21

P1476

Q38013995-0B750774-00B5-4A00-B2F3-1356598ACA63

P2093

Q38013995-B6FE0468-C7BD-44AC-AF54-794C0C89095D

Q38013995-C658D1B5-F99D-4D1B-BF2F-0944C8B10A69

Q38013995-D5F29CE9-21D6-4C83-BA6A-DD4C4B2C8FBA

P2860

Q38013995-015E4E36-807B-4837-9B6B-A37F982B7D99

Q38013995-04AB6374-384D-41B0-A6A7-D5E53385AFD5

Q38013995-067A6C55-55A7-49D3-8D26-F3EA3579E900

Q38013995-10620960-EDE1-4539-BEF7-6D564D49F265

Q38013995-111C3D99-BB94-4EEA-A2D7-01E1D4706645

Q38013995-1C2C66EF-8B96-48AF-A7AD-04D52EA2219F

Q38013995-1E88EFAC-D5A2-448C-91C4-1A78B42C6FCA

Q38013995-1FF3706D-6766-43BA-BEE4-D9C769CD88AB

Q38013995-29D11A38-4178-4DD3-AF5A-AFEE98990E0D

Q38013995-2A0A927F-EB32-4067-B562-9A04689AD4A4

P304

Q38013995-D4119393-3B1B-47A7-B048-C62D166D964B

P31

Q38013995-A4960D1C-FCE1-4D46-85E3-1A3AD0D818BC

P356

Q38013995-EFC0D088-D08C-40EE-88AF-1134A86573D7

P433

Q38013995-DFFC6180-E675-499B-98DA-ABCF6DCC2F33

P478

Q38013995-8959E6C1-7473-466F-A0AA-C209A4BF1D38

P577

Q38013995-14376F95-7908-47B2-A485-240938AE86E7

P5875

Q38013995-82C61757-6759-4273-8013-14F556B6E071

P698

Q38013995-1B380D4F-A079-4963-BE4F-07D41AA8A98C

P356

P1433

American Journal of Hematology

P1476

Lenalidomide in multiple myeloma: Current status and future potential.

@en

P2093

Andrew Spencer

http://www.w3.org/2001/XMLSchema#string

Anna Kalff

http://www.w3.org/2001/XMLSchema#string

Hang Quach

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.

P304

1089-1095

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.23234

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225069186

http://www.w3.org/2001/XMLSchema#string

P698

22641420

http://www.w3.org/2001/XMLSchema#string